Sanofi said on Wednesday it would review available information and
run consultations before deciding whether to enroll patients again for
its COVID-19-related hydroxychloroquine trials.
The French drugmaker said on May 29 it had stopped recruiting new
COVID-19 subjects for two clinical trials on hydroxychloroquine until
concerns about safety are cleared up following a decision by the World
Health Organization to pause a large trial.
The WHO said earlier in the day the trial would resume.
“We will review available information and run consultations in the
coming days to reassess our position,” a spokesman with Sanofi said.
https://www.reuters.com/article/us-health-coronavirus-sanofi-hydroxychlr/sanofi-to-run-consultations-over-restart-of-hydroxychloroquine-trials-idUSKBN23A2RU
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.